GLP-1s, Weight Loss, and the Stigma We Don’t Talk About
About this episode
Dr. Bret Scher discusses the stigma surrounding GLP-1 medications and the importance of integrating lifestyle changes for sustainable metabolic health.
A recent report highlighted a surprising trend: individuals using GLP-1 medications such as Ozempic and Wegovy may be facing even more social stigma than those who remain overweight. And while neither deserves any stigma at all, it raises an important question about how we judge health choices in modern medicine. In this conversation, Dr. Bret Scher reflects on whether his own critiques of GLP-1 medications stem from bias against the individuals using them. His conclusion is clear: the issue is not the patient, but the system surrounding care. While GLP-1 receptor agonists can be powerful tools for weight loss and metabolic improvement, Dr. Scher emphasizes a deeper concern: the growing tendency toward a “drug-first” model that may overlook foundational lifestyle and metabolic interventions such as nutrition quality, protein intake, resistance training, and long-term behavior change. Key themes discussed: The stigma patients face regardless of whether they lose weight or not The difference between criticizing a treatment and blaming the patient Concerns about overprescribing without adequate lifestyle support What happens when medications are stopped (and weight is regained) The…
More episodes of Metabolic Mind
- BITESIZE: New Study: Why Did This Drug Lower Cholesterol But Not Heart Plaque?
- Keto as an Adjunct to CBTp? Nicole Laurent Explains
- Q&A: Keto for PCOS, Cravings, & Women’s Health with Temple Stewart
- APA Hallway Talk: Are Psych Meds Overprescribed?
- Eggs and Alzheimer’s: New Study Challenges Assumptions
- Reversing & Preventing Fatty Liver with Metabolic Therapies | Dr. Adam Wolfberg
Explore listener stats, chart rankings, contacts and more on the Metabolic Mind podcast page.